Still a Smarter Way

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.

Subscribe to receive our free weekly newsletter in your inbox each Sunday morning.


Since our look at the larger Canadian LPs 12 weeks ago, when we shared a smarter way to invest in that sub-sector than Canopy Growth, our selections have all outperformed the stock, which has dropped 66.7%, substantially:

We are glad to see the better performance from the LPs we suggested, but they are still down rather substantially. Since then, the New Cannabis Ventures Global Cannabis Stock Index has declined 8.8%, so the declines in Cronos Group (11.9%), Village Farms (19.7%) and Organigram (30.5%) have been steep. We include the performance for Tilray, which 12 weeks ago was by far the leader of the group in 2023, as well. It has dropped more than the three stocks we suggested were superior to Canopy Growth, falling 40.1%.

While Canopy Growth has plunged and now trades below tangible book value (just 40% of it), we remain concerned. The company has a lot of debt, less cash than debt, a big operating loss currently and projected by analysts for the future and an accounting issue with its majority-controlled non-cannabis unit, BioSteel. We continue to believe that it likely won’t be successful with its plan to retain its NASDAQ listing and complete its American mergers and that it won’t succeed if it is able to do so. Speaking of NASDAQ listings, investors should be aware that the stock faces a risk of delisting due to the price being below $1.00.

Tilray has declined a great amount, though it remains expensive in our view. Unlike its peers, the stock trades at 2.5X tangible book value. The company has more debt than cash, and its profitability is low with weak growth. It will report its fiscal Q4 ending 5/31 in July or August. We understand that it is a very diversified company, but investors interested in cannabis can find better selections in other cannabis companies in our view. In fact, the three companies we are suggesting have a combined market cap of just 90% of the Tilray market cap of $990 million and a much lower enterprise value.

We discussed how inexpensive Cronos Group, Organigram and Village Farms were relative to their tangible book values 12 weeks ago, and they are even cheaper by this metric currently. The companies have better balance sheets and cash flows but trade very low relative to their tangible book values:

  • Cronos Group: 0.60X
  • Organigram: 0.42X
  • Village Farms: 0.34X

Village Farms has debt that exceeds its cash but that seems manageable. The company sold stock early this year that torpedoed the stock, but it is pursuing asset sales currently. Both Cronos Group and Organigram have a lot of cash and no debt, and each has a strategic investor. All of these companies do well in Canada but also have other markets in which they operate.

The Canadian cannabis market has matured and still has some regulatory issues. We view the lack of interest by investors in Canadian LPs as partially a reflection of the challenging environment there as well as in the cannabis sector overall, but the substantial declines in Canopy Growth and Tilray have played a role too. This week, StatsCan will be releasing April retail data for Canada, and the outlook at Hifyre isn’t great. Based on its point-of-sale data and its model, Hifyre projects retail cannabis sales will fall slightly sequentially in April relative to March. There is one less day, but the month had the 4/20 celebration. The 8.3% projected annual growth would be the lowest since the country legalized.

The three alternatives for Canopy Growth that we shared in late March have all outperformed it, but they have dropped sharply. We view these companies as very likely to recover their steep losses in the future and continue to suggest that owners of Canopy Growth and Tilray think about them as smarter investments.

Like this newsletter? Sign up, and you will receive a free copy by email each Sunday morning. Each week, we share the top stories and write an original perspective as well.

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:

Financial Reports

Aurora Q3 Cannabis Sales Slip 3% to C$53.3 Million

High Tide Q2 Revenue Flat to Q1 at C$118.1 Million

To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.

Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer the Canadian Cannabis LP Index, the American Cannabis Operator Index and the Ancillary Cannabis Index.

View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks.

Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.

Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.


Alan & Joel

Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter